Pylarify (piflufolastat f 18) injection
Active Awarded Last action
- Contract number
- 36C24824A0038
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 8
Veterans Health Administration, Department of Veterans Affairs
- Task orders
- 3 $2,345,668 obligated
Award facts
- Opportunity
-
- 6505--pylarify-piflufolastat F18 injection Special Notice · 36C24824Q1264 · Posted Jul 3, 2024
- Combined order value
-
- $2,345,668 Current, with exercised options
- $4,871,772 Potential, with all options
- Last date to order 54% complete
- IDV ceiling 89% used
- $2,634,365.60
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Veterans Integrated Service Network 8 (VISN 8), on behalf of the Department of Veterans Affairs, established a single-award Blanket Purchase Agreement with Progenics Pharmaceuticals Inc. on August 1, 2024, with a ceiling of $2,634,365.60 and a completion date of September 30, 2028, against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB).
The BPA procures PYLARIFY (piflufolastat F-18) injection, a radioactive diagnostic imaging agent used in positron emission tomography scans for prostate cancer detection and localization in VA medical centers. Performance occurs at the contractor's manufacturing and distribution facility in North Billerica, Massachusetts. The BPA incorporates FAR 52.222-90 addressing diversity, equity, and inclusion requirements under Executive Order 14398.
Three BPA calls have been issued under this vehicle. An initial call on August 1, 2024, was valued at $2,540,538.88. A second call issued October 1, 2024, for $1,129,529.36 added quantities and was scheduled for completion September 30, 2025. A modification issued October 1, 2025, for $902,180 increased quantities further, with completion scheduled for September 30, 2026. All calls are firm fixed-price with no set-aside designation. Progenics Pharmaceuticals operates as a division of Lantheus Medical Imaging, Inc.
Task orders
| Task order | Ordering agency | Obligated | Awarded |
|---|---|---|---|
| Pylarify (piflufolastat f 18) injection | Veterans Integrated Service Network 8 (VHA) | $1,201,704 | |
| Pylarify (piflufolastat f 18) injection | Veterans Integrated Service Network 8 (VHA) | $1,129,529 | |
| Pylarify | Veterans Integrated Service Network 8 (VHA) | $14,435 |
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36C24824A0038?
36C24824A0038 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 8 (Veterans Health Administration) on August 1, 2024.
How much is contract 36C24824A0038 worth?
Orders under 36C24824A0038 have obligated $2,345,668. Their combined potential value, with all options, is $4,871,772. 36C24824A0038's own ceiling is $2,634,366.
How many orders have been placed under contract 36C24824A0038?
3 orders have been placed under 36C24824A0038, the latest on October 1, 2025.
Who can order from contract 36C24824A0038?
36C24824A0038 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36C24824A0038 under another contract?
Yes. 36C24824A0038 is a blanket purchase agreement under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24824A0038 competed?
The extent of competition for 36C24824A0038 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV